{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:04:42Z","timestamp":1792919082609,"version":"4.5.0"},"reference-count":14,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A minority of patients with follicular lymphoma (FL) undergo histological transformation (HT). This retrospective analysis of 549 patients from the phase 3 GALLIUM study (NCT01332968) assessed the relationship between maximum standardized uptake value (SUVmax) at baseline on positron emission tomography (PET) and HT risk. Previously untreated patients with high tumor burden grade 1-3a FL received obinutuzumab- or rituximab-based chemotherapy induction. The relationship between baseline SUVmax (bSUVmax) and HT risk was assessed using cutoff values for SUVmax &amp;gt;10 and &amp;gt;20. Overall, 15 of 549 (2.7%) patients with baseline PET scans experienced biopsy-confirmed HT (median follow-up, 59 months). More than 65% of patients had bSUVmax &amp;gt; 10, with 3.3% of these experiencing HT. Only 1 of 74 (1.4%) patients with bSUVmax &amp;gt; 20 underwent HT. Median bSUVmax in patients with HT vs without HT was 12.4 (range, 8.1-28.0) vs 11.8 (range, 3.1-64.4), respectively; median bSUVrange (the difference between bSUVmax of the most and least 18F-fluorodeoxyglucose\u2013avid lymphoma sites) was 8.0 (range, 1.1-23.9) vs 7.1 (range, 0.0-59.8), respectively. There was no temporal relationship between bSUVmax and HT. Neither bSUVmax nor bSUVrange predicted HT in GALLIUM, suggesting that there may be little benefit in rebiopsy of lesions to exclude HT based on SUVmax alone before initiating therapy in patients with high tumor burden FL.<\/jats:p>","DOI":"10.1182\/blood.2019001091","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T20:49:50Z","timestamp":1579639790000},"page":"1214-1218","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study"],"prefix":"10.1182","volume":"135","author":[{"given":"Farheen","family":"Mir","sequence":"first","affiliation":[{"name":"Royal Marsden Hospital, Sutton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-5288","authenticated-orcid":false,"given":"Sally F.","family":"Barrington","sequence":"first","affiliation":[{"name":"King\u2019s College London and Guy\u2019s and St Thomas\u2019 Positron Emission Tomography Centre, School of Biomedical Engineering and Imaging Sciences, King\u2019s College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Brown","sequence":"first","affiliation":[{"name":"Roche Products Ltd, Welwyn, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Nielsen","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Sahin","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Meignan","sequence":"first","affiliation":[{"name":"Functional Imaging and Therapeutics Department, H\u00f4pital Henri Mondor and Universit\u00e9 Paris-Est Cr\u00e9teil, Cr\u00e9teil, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"first","affiliation":[{"name":"Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2020040911580041900_B1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"8","key":"2020040911580041900_B2","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"2020040911580041900_B3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"2020040911580041900_B4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.114.149625","article-title":"18F-FDG or 3\u2032-deoxy-3\u2032-18F-fluorothymidine to detect transformation of follicular lymphoma","volume":"56","author":"Wondergem","year":"2015","journal-title":"J Nucl Med"},{"issue":"3","key":"2020040911580041900_B5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/MNM.0b013e328342b9d2","article-title":"Features of large cell transformation of indolent lymphomas as observed on sequential PET\/CT","volume":"32","author":"Karam","year":"2011","journal-title":"Nucl Med Commun"},{"issue":"21","key":"2020040911580041900_B6","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin\u2019s lymphoma","volume":"23","author":"Sch\u00f6der","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020040911580041900_B7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdp030","article-title":"High SUV uptake on FDG-PET\/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET\/CT staging in lymphoma","volume":"20","author":"Ngeow","year":"2009","journal-title":"Ann Oncol"},{"issue":"3","key":"2020040911580041900_B8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","author":"Bodet-Milin","year":"2008","journal-title":"Haematologica"},{"issue":"14","key":"2020040911580041900_B9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2020040911580041900_B10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.hoc.2007.06.011","article-title":"The International Harmonization Project for response criteria in lymphoma clinical trials","volume":"21","author":"Cheson","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"issue":"21","key":"2020040911580041900_B11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/blood.V124.21.1629.1629","article-title":"SUVmax on pre-treatment FDG PET scan is not predictive of outcome in follicular lymphoma after R-CHOP therapy","volume":"124","author":"Ahmed","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2020040911580041900_B12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood.V128.22.1101.1101","article-title":"Low SUVmax measured on baseline FDG-PET\/CT and elevated \u03b22 microglobulin are negative predictors of outcome in high tumor burden follicular lymphoma treated by immunochemotherapy: a pooled analysis of three prospective studies","volume":"128","author":"Cottereau","year":"2016","journal-title":"Blood"},{"issue":"47","key":"2020040911580041900_B13","doi-asserted-by":"crossref","first-page":"e8705","DOI":"10.1097\/MD.0000000000008705","article-title":"18F-fluorodeoxyglucose positron emission tomography computed tomography detection threshold in follicular lymphoma: a case report","volume":"96","author":"P\u00e9ricart","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"22","key":"2020040911580041900_B14","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA Trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/15\/1214\/1723172\/bloodbld2019001091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/15\/1214\/1723172\/bloodbld2019001091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T16:04:32Z","timestamp":1586448272000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/15\/1214\/431272\/Baseline-SUVmax-did-not-predict-histological"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":14,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001091","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]}}}